Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice

Clinical and Experimental Hypertension

Volumn 34, Issue 2, 2012, Pages 113-117

  Cicero, Arrigo F G ^a   Gerocarni, Beatrice ^a   Rosticci, Martina ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Combination therapy; Hypertension; Lercanidipine; Metabolic effect; Monotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LERCANIDIPINE; TRIACYLGLYCEROL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLISM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MIDDLE AGED; TRIGLYCERIDES;

EID: 84859597064     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.601381     Document Type: Article

References (20)

1. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ 2008; 336(7653):1121-1123. (Pubitemid 351731743)
2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303(20):2043-2050.
3. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: Cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17(5):530-540.
4. Viera AJ, Schmid D, Bostrom S, et al. Level of blood pressure above goal and clinical inertia in a Medicaid population. J Am Soc Hypertens 2010; 4(5):244-254.
5. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 2010; 375(9718):906-915.
6. Burnier M, Pruijm M, Wuerzner G. Treatment of essential hypertension with calcium channel blockers: What is the place of lercanidipine? Expert Opin Drug Metab Toxicol 2009; 5(8):981-987.
7. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 2009; 31(8):1652-1663.
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25(9):1751-1762. (Pubitemid 47356612)
9. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111(5):697-716. (Pubitemid 40216499)
10. Borghi C, Veronesi M, Cosentino E, et al. Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with highnormal blood pressure. J Hypertens 2007; 25(10):2051-2057. (Pubitemid 47476301)
11. Israili ZH, Lyoussi B, Hernández-Hernández R, Velasco M. Metabolic syndrome: Treatment of hypertensive patients. Am J Ther 2007; 14(4):386-402. (Pubitemid 47224822)
12. Wu JR, Liou SF, Lin SW, et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59(1): 48-56.
13. Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41(4):950-955. (Pubitemid 36418471)
14. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: The oxidative stress. Nutr Metab Cardiovasc Dis 2010; 20(1):72-77.
15. Viviani GL. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40(1):133-139. (Pubitemid 34705540)
16. Duvnjak L, Duvnjak M. The metabolic syndrome - an ongoing story. J Physiol Pharmacol 2009; 60(Suppl. 7):19-24.
17. Robles NR, Romero B, de Vinuesa EG, Sánchez-Casado E, Cubero JJ. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32(2):192-197.
18. Borghi C, Cicero AFG. Rationale for the use of fixed-dose combination in the management of hypertension: Efficacy and tolerability of lercanidipine plus enalapril. Clin Drug Invest 2010; 30(12):843-854.
19. Prandin MG, Cicero AF, Veronesi M, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: A prospective evaluation. Clin Exp Hypertens 2007; 29(8):553-562. (Pubitemid 350223249)
20. Simons LA, OrtizM, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006. Med J Aust 2008; 188(4):224-227.